Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chitosan-Based Nanocarriers Co-Delivering Pioglitazone and Curcumin: Biological Activity and Therapeutic Potential in Diabetes.

International journal of molecular sciences·2026

Same author

Acute Toxicity of Three Synthetic Cannabinoids: First In Vivo Preclinical Study.

Molecules (Basel, Switzerland)·2026

Same author

EEG Neurofeedback for Major Depressive Disorder: A Scoping Review.

Alpha psychiatry·2026

Same author

Natural products modulate social behavior and gut microbiota in a valproic acid-induced zebrafish model of autism spectrum disorder.

Biomolecules & biomedicine·2026

Same author

MRI-Based Brain Signatures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Systematic Review and Meta-Analysis.

Diagnostics (Basel, Switzerland)·2026

Same author

Cannabinoids and opioid consumption in cancer pain: a systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Administration of Δ⁹-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Navigating dose-effect complexities and challenges in cannabinoid therapy for aging-related neurobiological changes.

Ivona-Maria Tudorancea¹, Leontina-Elena Filipiuc¹, Diana-Sabina Vieru²

¹Advanced Research and Development Center for Experimental Medicine "Prof. Ostin C. Mungiu" CEMEX, "Grigore T. Popa" University of Medicine and Pharmacy of Iasi, Iasi, Romania.

Frontiers in Pharmacology

|June 15, 2026

Summary

Tetrahydrocannabinol (THC) shows dual effects in the aging brain, with low doses potentially neuroprotective and high doses neurodisruptive. Cannabidiol (CBD) appears neuroprotective, but age-specific strategies are needed for both cannabinoids.

Keywords:

aging blood brain barrier cannabidiol cannabinoids neuroinflammation pharmacokinetic tetrahydrocannabinol

More Related Videos

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

Related Experiment Videos

Last Updated: Jun 16, 2026

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Administration of Δ⁹-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

Area of Science:

Neuroscience
Pharmacology
Aging Research

Background:

Brain aging involves complex molecular and cellular changes.
The endocannabinoid system regulates brain homeostasis during aging.
The neurological impact of cannabinoids in aging brains is not fully understood.

Purpose of the Study:

To review preclinical and clinical evidence on age-dependent effects of THC and CBD.
To analyze dose, administration route, and pharmacokinetics in aging.
To clarify the polarized interpretations of cannabinoid effects in aging brains.

Main Methods:

Narrative review synthesizing existing research.
Critical analysis of studies on tetrahydrocannabinol (THC) and cannabidiol (CBD).
Emphasis on dose-dependent and age-related effects.

Main Results:

THC has a dual dose-dependent effect: low doses may be neuroprotective, while high doses can cause neuroinflammation and impairment.
CBD shows promising anti-neuroinflammatory, antioxidant, and neuroprotective effects in aging models.
Aging influences cannabinoid pharmacokinetics, impacting their effects.

Conclusions:

THC therapies may have dual effects in the aging brain, necessitating age-adapted dosing.
CBD appears generally neuroprotective in aging, though developmental effects require more study.
Integrated experimental approaches are crucial for defining cannabinoid therapeutic potential in age-associated neurological disorders.